Crushing lopinavir-ritonavir tablets may decrease the efficacy of therapy in COVID-19 patients.

Eljaaly, Khalid; Al-Tawfiq, Jaffar A

Eljaaly, Khalid; Al-Tawfiq, Jaffar A.

Eljaaly K; Department of Pharmacy Practice, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia; Pharmacy Practice and Science Department, College of Pharmacy, University of Arizona, Tucson, AZ, USA. Electronic address: keljaaly@kau.edu.sa.
Al-Tawfiq JA; Infectious Disease Unit, Specialty Internal Medicine, Johns Hopkins Aramco Healthcare, Dhahran, Saudi Arabia; Department of Medicine, Indiana University, School of Medicine, Indianapolis, IN, USA; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Travel Med Infect Dis ; 38: 101749, 2020.

Article in English | MEDLINE | ID: covidwho-401707

Subject(s)

COVID-19; Ritonavir; Adult; Humans; Lopinavir/therapeutic use; Ritonavir/therapeutic use; SARS-CoV-2; Tablets

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Ritonavir / COVID-19 Limits: Adult / Humans Language: English Journal: Travel Med Infect Dis Journal subject: Communicable Diseases Year: 2020 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google